The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy

• Published in: International journal of molecular sciences 2021-05, Vol.22 (11), p.5438
• Main Authors: Kouhpayeh, Shirin, Shariati, Laleh, Boshtam, Maryam, Rahimmanesh, Ilnaz, Mirian, Mina, Esmaeili, Yasaman, Najaflu, Malihe, Khanahmad, Negar, Zeinalian, Mehrdad, Trovato, Maria, Tay, Franklin R, Khanahmad, Hossein, Makvandi, Pooyan
• Format: Article
• Language: English
• Subjects: Apoptosis - drug effects; Cholecalciferol - pharmacology; clinical manifestations; coronavirus; COVID-19; COVID-19 - metabolism; COVID-19 - physiopathology; COVID-19 - therapy; COVID-19 Drug Treatment; Cytokine Release Syndrome - drug therapy; GTPase-Activating Proteins - antagonists & inhibitors; GTPase-Activating Proteins - metabolism; Humans; Nanomedicine - methods; oxidative stress; Oxidative Stress - drug effects; PARG; PARP; Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors; Poly (ADP-Ribose) Polymerase-1 - metabolism; Renin-Angiotensin System - drug effects; Review; SARS-CoV-2 - drug effects; SARS-CoV-2 - growth & development; SARS-CoV-2 - metabolism; Tannins - pharmacology; Trehalose - pharmacology; TRPM Cation Channels - antagonists & inhibitors; TRPM Cation Channels - metabolism
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms22115438

In late 2019, a new member of the Coronaviridae family, officially designated as "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2), emerged and spread rapidly. The Coronavirus Disease-19 (COVID-19) outbreak was accompanied by a high rate of morbidity and mortality worldwide and was declared a pandemic by the World Health Organization in March 2020. Within the Coronaviridae family, SARS-CoV-2 is considered to be the third most highly pathogenic virus that infects humans, following the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV). Four major mechanisms are thought to be involved in COVID-19 pathogenesis, including the activation of the renin-angiotensin system (RAS) signaling pathway, oxidative stress and cell death, cytokine storm, and endothelial dysfunction. Following virus entry and RAS activation, acute respiratory distress syndrome develops with an oxidative/nitrosative burst. The DNA damage induced by oxidative stress activates poly ADP-ribose polymerase-1 (PARP-1), viral macrodomain of non-structural protein 3, poly (ADP-ribose) glycohydrolase (PARG), and transient receptor potential melastatin type 2 (TRPM2) channel in a sequential manner which results in cell apoptosis or necrosis. In this review, blockers of angiotensin II receptor and/or PARP, PARG, and TRPM2, including vitamin D3, trehalose, tannins, flufenamic and mefenamic acid, and losartan, have been investigated for inhibiting RAS activation and quenching oxidative burst. Moreover, the application of organic and inorganic nanoparticles, including liposomes, dendrimers, quantum dots, and iron oxides, as therapeutic agents for SARS-CoV-2 were fully reviewed. In the present review, the clinical manifestations of COVID-19 are explained by focusing on molecular mechanisms. Potential therapeutic targets, including the RAS signaling pathway, PARP, PARG, and TRPM2, are also discussed in depth.